PHAF DIC Team

Approval of new treatment for adults with partial-onset seizures

PHAF Team

Apremilast approved for oral ulcers associated with Behçet’s Disease

PHAF Team

AirDuo Digihaler got green signal from FDA

PHAF DIC Team

Crizanlizumab-tmca approved for sickle cell disease

PHAF Team

First generic drug for pain from nerve damage

PHAF Team

Katerzia (amlodipine) Oral Suspension Approved for Pediatric Patients 6 Years of Age and Older

PHAF Team

New drug for treatment-resistant forms of tuberculosis that affects the lungs

PHAF Team

New treatment for complicated urinary tract and complicated intra-abdominal infections

PHAF Team

Xpovio (selinexor) Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myelo

Approvals

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.